Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer who are progressed after standard chemotherapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 13 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.